case_images: PMC7383634_01
case_images: Abdominal aorta atheromatous plaque (arrowhead) at (a) nivolumab start and (b) resolution after treatment.
case_images: 10.1177_1758835920913801-fig1.jpg
case_images: PMC7383634_01_10.1177_1758835920913801-fig1.jpg
case_images: fig1-1758835920913801
case_images: Before treatment with nivolumab, a CT scan demonstrated a complicated atheromatous plaque in the abdominal aorta wall (Figure 1a), that almost completely resolved while on nivolumab (Figure 1b), as previously reported.
case_images: Thoracic aorta atheromatous plaque (arrowhead) at (a) atezolizumab start and (b) resolution after 4 months of treatment.
case_images: 10.1177_1758835920913801-fig2.jpg
case_images: PMC7383634_01_10.1177_1758835920913801-fig2.jpg
case_images: fig2-1758835920913801
case_images: At the time atezolizumab was started, a computed tomography (CT) scan demonstrated the appearance of a new complicated atheromatous plaque in the thoracic aorta (Figure 2a). Interestingly, after 4 months of atezolizumab, the thoracic aorta plaque considerably improved again until nearly complete resolution (Figure 2b).
case_images: Pathologic soft tissue at right hilum (arrowhead) at (a) atezolizumab start and (b) its reduction after 4 months of treatment consisting with disease response.
case_images: 10.1177_1758835920913801-fig3.jpg
case_images: PMC7383634_01_10.1177_1758835920913801-fig3.jpg
case_images: fig3-1758835920913801
case_images: In addition, partial response of disease was observed (Figure 3) so the patient is still on treatment.